Moderna, the company co-founded and led by Armenian-American scientist, businessman and philanthropist Noubar Afeyan, today presented preliminary information on the first phase of trials of a vaccine against the coronavirus.
Specifically, in all 45 volunteers, the vaccine produced antibodies, thereby opening a path to fighting the infection.
The volunteers, divided into groups of 15, received 25, 100 and 250 micrograms of the vaccine respectively, twice, 28 days apart.
Earlier, Moderna’s chief executive Stéphane Bancel had stated that trials of a vaccine against the COVID-19 pandemic, involving 600 people, would begin in July.
Moderna’s vaccine “candidate,” mRNA-1273, is based on genetic material, is developed according to a very specific formula, and produces proteins of the coronavirus. Since the virus, as a rule, uses that protein to “blockade” lung cells, this vaccine can create a healthy immune system to produce antibodies before infection.
